SCHEMBL25368947

SCHEMBL25368947

Cc1nc(-c2cccc(NC(=O)c3csc(C(=O)Nc4cccc(NS(C)(=O)=O)c4)c3)c2)cs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.69
▸ MAPT P10636 7/20 0.62
▸ BRD4 O60885 1/20 0.57
▸ HPGD P15428 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ NPC1 O15118 4/20 0.53
▸ RAB9A P51151 4/20 0.53
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ NFKB1 P19838 3/20 0.53
▸ NFKB2 Q00653 3/20 0.53
▸ RELA Q04206 3/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ LMNA P02545 4/20 0.51
▸ TP53 P04637 2/20 0.48
▸ KDM1A O60341 1/20 0.48
▸ GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30543863 1.00 HTT (0.69) HTTMAPTBRD4HPGDALDH1A1
SCHEMBL19626761 0.83 HTT (1.00) HTTMAPTHPGDALDH1A1NPC1
SCHEMBL30543946 0.82 DHX9 (0.53) HTTMAPTHPGDALDH1A1RAB9A
SCHEMBL25368280 0.82 DHX9 (0.53) HTTMAPTHPGDALDH1A1RAB9A
SCHEMBL30544073 0.82 NAMPT (0.53) HTTLMNA
SCHEMBL25366609 0.82 NAMPT (0.53) HTTLMNA
SCHEMBL25369304 0.80 DHX9 (0.52) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL30544037 0.80 DHX9 (0.52) HTTHPGDALDH1A1MEN1KMT2A
SCHEMBL26043268 0.80 HTT (0.58) HTTMAPTBRD4HPGDALDH1A1
SCHEMBL25367459 0.79 ALDH1A1 (0.51) HTTMAPTHPGDALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B HTT 1031/4885MAPT 3830/4885BRD4 2253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback